Highslab Therapeutics

Highslab Therapeutics is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company utilizes a proprietary high-throughput screening platform designed to identify highly selective modulators for historically difficult-to-drug GPCR targets. Their current research efforts are primarily directed toward addressing unmet needs in metabolic diseases, chronic inflammation, and neurological disorders. By leveraging advanced structural biology and computational chemistry, Highslab aims to accelerate the transition of lead compounds into clinical development. The company operates as a private entity, focusing on building a robust early-stage pipeline through internal R&D and strategic academic collaborations.